SC 13G/A

NAMES OF REPORTING PERSONS

Clarus Lifesciences III, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SC 13G/A 1 d133130dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Tourmaline Bio, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

89157D105

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

CUSIP No. 89157D105

Item 1(a).

Name of Issuer

Tourmaline Bio, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Office

27 West 24th Street, Suite 702, New York, NY 10010

Item 2(a).

Name of Person Filing

Item 2(b).

Address of Principal Business Office

Item 2(c).

Citizenship

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

(i)

Clarus Lifesciences III, L.P.

c/o Blackstone Inc.

345 Park Avenue

New York, NY 10154

SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)